Evaluating immunosuppressive therapy for IgA nephropathy in patients with advanced chronic kidney disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to assess the long-term efficacy and safety of low-dose oral corticosteroids combined with cyclophosphamide therapy, as well as low-dose corticosteroids monotherapy, in patients with IgA nephropathy who have stage 3 or 4 chronic kidney disease. Participants will receive maximal renin-angiotensin system (RAS) inhibitor therapy alongside these treatments. The study focuses on patients with biopsy-proven IgA nephropathy and significant proteinuria despite optimal RAS blockade. The goal is to determine the best therapeutic approach to manage this condition effectively.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Biopsy-proven IgA nephropathy;
* Proteinuria ≥1.0g/day while receiving maximum tolerated dose of RAS blockade;
* Estimated glomerular filtration rate 15-60 ml/min/1.73/m2.

Exclusion Criteria:

* Indication or contraindication for immunosuppressive therapy with corticosteroids
* Use of corticosteroids and other immunosuppressive drugs within the last 1 year
* Current unstable kidney function for other reasons
* Under 18 years old
* Patients with secondary IgAN
* Patients who are unlikely to comply with the study protocol in the view of the treating physician

Where it's running

• Afmmu
  Xi'an, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Long-term zigakibart treatment for adults with IgA nephropathy

  Adults with IgA nephropathy who finished an earlier zigakibart trial will receive ongoing subcutaneous zigakibart every two weeks to see if it stays safe and helps over the long term.

  Recruiting at 26 sites Phase 3 Novartis · Denver, Colorado and 25 other locations · NCT06858319

• Iptacopan added to standard care to change kidney biopsy findings in adults with IgA nephropathy

  This will try iptacopan added to standard treatment for adults with biopsy-confirmed IgA nephropathy to see if it reduces mesangial complement (C3c) deposits and improves kidney biomarkers over 9 months.

  Recruiting at 19 sites Phase 2 Novartis · Birmingham, Alabama and 18 other locations · NCT06797518

• Investigating T cell ratios in patients with IgA nephropathy

  This study is testing if measuring certain types of immune cells in the blood can help doctors tell the difference between stable and worsening IgA nephropathy in patients.

  Recruiting Centre Hospitalier Universitaire de Besancon · Besançon · NCT05791162

• Sparsentan for IgA Nephropathy: safety and activity in adults with incident IgAN and recurrent IgAN after transplant

  This trial tests whether sparsentan can be safely given and help kidney outcomes in adults with immunoglobulin A nephropathy, including people newly diagnosed who haven’t had ACEI/ARB therapy and people with recurrent IgAN after kidney transplant.

  Recruiting at 6 sites Phase 2 University of Leicester · Cambridge, England and 5 other locations · NCT04663204

• Data repository for kidney diseases and related conditions

  This study is collecting health information and samples from people with different kidney diseases to see how various factors affect their condition and treatment.

  Recruiting The Rogosin Institute · New York, New York · NCT01802034

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.